en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
2/2012
vol. 50
 
Share:
Share:
more
 
 
abstract:
Short communication

Polymyositis, dermatomyositis and inclusion body myositis

Eugeniusz J. Kucharz
,
Małgorzata Widuchowska
,
Magdalena Kopeć-Mędrek
,
Anna Kotulska

Reumatologia 2012; 50, 2: 119–123
Online publish date: 2012/06/01
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Idiopathic inflammatory myopathy is a group of diseases of unknown aetiology and probably autoimmune pathogenesis (Tables I, II). Treatment of the diseases is divided into the following stages: initial phase, intermediate phase, and long-lasting therapy. Glucocorticoids and other immunosuppressive drugs (commonly azathioprine and methotrexate) are applied for management. It is important to evaluate activity of the disease, effectiveness of the treatment and occurrence of adverse reactions. Inclusion body myositis is resistant to glucocorticoid therapy.
keywords:

polymyositis, dermatomyositis, glucocorticoids, steroid myopathy







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.